Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma

Over the past decades, immunomodulatory drugs, pro-teasome inhibitors, and targeted antibodies have significantly improved the overall survival of multiple myeloma (MM) patients. Nonetheless, the disease remains incurable as patients ultimately develop resistance to all available modalities. One of